CD40 Induces Antigen Transporter and Immunoproteasome Gene Expression in Carcinomas via the Coordinated Action of NF-κB and of NF-κB-Mediated De Novo Synthesis of IRF-1

REFERENCES

• Arons, E., V. Kunin, C. Schechter, and R. Ehrlich. 2001. Organization and functional analysis of the mouse transporter associated with antigen processing 2 promoter. J. Immunol. 166:3942–3951.
   PubMedGoogle Scholar
• Bennett, B. L., D. T. Sasaki, B. W. Murray, E. C. O'Leary, S. T. Sakata, W. Xu, J. C. Leisten, A. Motiwala, S. Pierce, Y. Satoh, S. S. Bhagwat, A. M. Manning, and D. W. Anderson. 2001. SP600125, an anthrapyrazolone inhibitor of Jun N-terminal kinase. Proc. Natl. Acad. Sci. USA 98:13681–13686.
   PubMed Web of Science ®Google Scholar
• Callard, R. E., R. J. Armitage, W. C. Fanslow, and M. K. Spriggs. 1993. CD40 ligand and its role in X-linked hyper-IgM syndrome. Immunol. Today 14:559–564.
   PubMedGoogle Scholar
• Challa, A., A. G. Eliopoulos, M. J. Holder, A. S. Burguete, J. D. Pound, A. Chamba, G. Grafton, R. J. Armitage, C. D. Gregory, H. Martinez-Valdez, L. Young, and J. Gordon. 2002. Population depletion activates autonomous CD154-dependent survival in biopsylike Burkitt lymphoma cells. Blood 99:3411–3418.
   PubMed Web of Science ®Google Scholar
• Chatterjee-Kishore, M., R. Kishore, D. J. Hicklin, F. M. Marincola, and S. Ferrone. 1998. Different requirements for signal transducer and activator of transcription 1α and interferon regulatory factor 1 in the regulation of low molecular mass polypeptide 2 and transporter associated with antigen processing 1 gene expression. J. Biol. Chem. 273:16177–16183.
   PubMedGoogle Scholar
• Cromme, F. V., J. Airey, M. T. Heemels, H. L. Ploegh, P. J. Keating, P. L. Stern, C. J. Meijer, and J. M. Walboomers. 1994. Loss of transporter protein, encoded by the TAP-1 gene, is highly correlated with loss of HLA expression in cervical carcinomas. J. Exp. Med. 179:335–340.
   PubMed Web of Science ®Google Scholar
• Davies, C. C., D. Bem, L. S. Young, and A. G. Eliopoulos. 2005. NF-kappaB overrides the apoptotic program of TNF receptor 1 but not CD40 in carcinoma cells. Cell. Signal. 17:729–738.
   PubMedGoogle Scholar
• Davies, C. C., T. W. Mak, L. S. Young, and A. G. Eliopoulos. 2005. TRAF6 is required for TRAF2-dependent CD40 signal transduction in nonhemopoietic cells. Mol. Cell. Biol. 25:9806–9819.
   PubMedGoogle Scholar
• Davies, C. C., J. Mason, M. J. Wakelam, L. S. Young, and A. G. Eliopoulos. 2004. Inhibition of phosphatidylinositol 3-kinase- and ERK MAPK-regulated protein synthesis reveals the pro-apoptotic properties of CD40 ligation in carcinoma cells. J. Biol. Chem. 279:1010–1019.
   PubMedGoogle Scholar
• Dornan, D., M. Eckert, M. Wallace, H. Shimizu, E. Ramsay, T. R. Hupp, and K. L. Ball. 2004. Interferon regulatory factor 1 binding to p300 stimulates DNA-dependent acetylation of p53. Mol. Cell. Biol. 24:10083–10098.
   PubMedGoogle Scholar
• Dudley, D. T., L. Pang, S. J. Decker, A. J. Bridges, and A. R. Saltiel. 1995. A synthetic inhibitor of the mitogen-activated protein kinase cascade. Proc. Natl. Acad. Sci. USA 92:7686–7689.
   PubMed Web of Science ®Google Scholar
• Eliopoulos, A. G., C. W. Dawson, G. Mosialos, J. E. Floettmann, M. Rowe, R. J. Armitage, J. Dawson, J. M. Zapata, D. J. Kerr, M. J. O. Wakelam, J. C. Reed, E. Kieff, and L. S. Young. 1996. CD40-induced growth inhibition in epithelial cells is mimicked by Epstein-Barr virus-encoded LMP1: involvement of TRAF3 as a common mediator. Oncogene 13:2243–2254.
   PubMed Web of Science ®Google Scholar
• Eliopoulos, A. G., C. C. Wang, C. D. Dumitru, and P. N. Tsichlis. 2003. Tpl2 transduces CD40 and TNF signals that activate ERK and regulates IgE induction by CD40. EMBO J. 22:3855–3864.
   PubMed Web of Science ®Google Scholar
• Eliopoulos, A. G., and L. S. Young. 2004. The role of the CD40 pathway in the pathogenesis and treatment of cancer. Curr. Opin. Pharmacol. 4:360–367.
   PubMed Web of Science ®Google Scholar
• Elliott, T., and A. Williams. 2005. The optimization of peptide cargo bound to MHC class I molecules by the peptide-loading complex. Immunol. Rev. 207:89–99.
   PubMedGoogle Scholar
• Forero-Torres, A., R. R. Furman, J. D. Rosenblatt, A. Younes, K. Harrop, and J. G. Drachman. 2006. A humanized antibody against CD40 (SGN-40) is well tolerated and active in non-Hodgkin's lymphoma (NHL): results of a phase 1 study. J. Clin. Oncol. 24:430s.
   Google Scholar
• Foss, G. S., and H. Prydz. 1999. Interferon regulatory factor 1 mediates the interferon-gamma induction of the human immunoproteasome subunit multicatalytic endopeptidase complex-like 1. J. Biol. Chem. 274:35196–35202.
   PubMed Web of Science ®Google Scholar
• French, R. R., H. T. C. Chan, A. L. Tutt, and M. J. Glennie. 1999. CD40 antibody evokes a cytotoxic T-cell response that eradicates lymphoma and bypasses T cell help. Nat. Med. 5:548–553.
   PubMedGoogle Scholar
• Fujita, T., Y. Kimura, M. Miyamoto, E. L. Barsoumian, and T. Taniguchi. 1989. Induction of endogenous IFN-alpha and IFN-beta genes by a regulatory transcription factor, IRF-1. Nature 337:270–272.
   PubMed Web of Science ®Google Scholar
• Fujita, T., L. F. Reis, N. Watanabe, Y. Kimura, T. Taniguchi, and J. Vilcek. 1989. Induction of the transcription factor IRF-1 and interferon-beta mRNAs by cytokines and activators of second-messenger pathways. Proc. Natl. Acad. Sci. USA 86:9936–9940.
   PubMed Web of Science ®Google Scholar
• Funakoshi, S., D. L. Longo, M. Beckwith, D. K. Conley, G. Tsarfaty, I. Tsarfaty, R. J. Armitage, W. C. Fanslow, M. K. Spriggs, and W. J. Murphy. 1994. Inhibition of human B-cell lymphoma growth by CD40 stimulation. Blood 83:2787–2794.
   PubMed Web of Science ®Google Scholar
• Gabathuler, R., G. Reid, G. Kolaitis, J. Driscoll, and W. A. Jefferies. 1994. Comparison of cell lines deficient in antigen presentation reveals a functional role for TAP-1 alone in antigen processing. J. Exp. Med. 180:1415–1425.
   PubMed Web of Science ®Google Scholar
• Gallagher, E., T. Enzler, A. Matsuzawa, A. Anzelon-Mills, D. Otero, R. Holzer, E. Janssen, M. Gao, and M. Karin. 2007. Kinase MEKK1 is required for CD40-dependent activation of the kinases Jnk and p38, germinal center formation, B cell proliferation and antibody production. Nat. Immunol. 8:57–63.
   PubMedGoogle Scholar
• Galon, J., C. Sudarshan, S. Ito, D. Finbloom, and J. J. O'Shea. 1999. IL-12 induces IFN regulating factor-1 (IRF-1) gene expression in human NK and T cells. J. Immunol. 162:7256–7262.
   PubMed Web of Science ®Google Scholar
• Ghamande, S., B. L. Hylander, E. Oflazoglu, S. Lele, W. Fanslow, and E. A. Repasky. 2001. Recombinant CD40 ligand therapy has significant antitumor effects on CD40-positive ovarian tumor xenografts grown in SCID mice and demonstrates an augmented effect with cisplatin. Cancer Res. 61:7556–7562.
   PubMed Web of Science ®Google Scholar
• Grups, J. W., and H. G. Frohmuller. 1988. Antiproliferative effects of interferons against human bladder carcinoma cell lines in vitro. Urol. Int. 43:265–268.
   PubMedGoogle Scholar
• Hayden, M. S., and S. Ghosh. 2004. Signaling to NF-κB. Genes Dev. 18:2195–2224.
   PubMed Web of Science ®Google Scholar
• Hayward, A. R., J. Levy, F. Facchetti, L. Notarangelo, H. D. Ochs, A. Etzioni, J.-Y. Bonnefoy, M. Cosyns, and A. Weinberg. 1997. Cholangiopathy and tumours of the pancreas, liver and biliary tree in boys with X-linked immunodeficiency with hyper-IgM. J. Immunol. 158:977–983.
   PubMed Web of Science ®Google Scholar
• Hill, S. C., S. J. Youde, S. Man, G. R. Teale, A. J. Baxendale, A. Hislop, C. C. Davies, D. M. Luesley, A. M. Blom, A. B. Rickinson, L. S. Young, and A. G. Eliopoulos. 2005. Activation of CD40 in cervical carcinoma cells facilitates CTL responses and augments chemotherapy-induced apoptosis. J. Immunol. 174:41–50.
   PubMed Web of Science ®Google Scholar
• Kato, T., R. Hakamada, H. Yamane, and H. Nariuchi. 1996. Induction of IL-12 p40 messenger RNA expression and IL-12 production of macrophages via CD40-CD40 ligand interaction. J. Immunol. 156:3932–3938.
   PubMedGoogle Scholar
• Khanna, R., L. Cooper, N. Kienzle, D. J. Moss, S. R. Burrows, and K. K. Khanna. 1997. Engagement of CD40 antigen with soluble CD40 ligand up-regulates peptide transporter expression and restores endogenous processing function in Burkitt's lymphoma cells. J. Immunol. 159:5782–5785.
   PubMed Web of Science ®Google Scholar
• Kikuchi, T., and R. G. Crystal. 1999. Anti-tumor immunity induced by in vivo adenovirus vector-mediated expression of CD40 ligand in tumor cells. Hum. Gene Ther. 10:1375–1387.
   PubMed Web of Science ®Google Scholar
• Kim, P. K., M. Armstrong, Y. Liu, P. Yan, B. Bucher, B. S. Zuckerbraun, A. Gambotto, T. R. Billiar, and J. H. Yim. 2004. IRF-1 expression induces apoptosis and inhibits tumor growth in mouse mammary cancer cells in vitro and in vivo. Oncogene 23:1125–1135.
   PubMed Web of Science ®Google Scholar
• Kishore, N., C. Sommers, S. Mathialagan, J. Guzova, M. Yao, S. Hauser, K. Huynh, S. Bonar, C. Mielke, L. Albee, R. Weier, M. Graneto, C. Hanau, T. Perry, and C. S. Tripp. 2003. A selective IKK-2 inhibitor blocks NF-kappa B-dependent gene expression in interleukin-1 beta-stimulated synovial fibroblasts. J. Biol. Chem. 278:32861–32871.
   PubMed Web of Science ®Google Scholar
• Kroger, A., A. Stirnweiss, J. E. Pulverer, K. Klages, M. Grashoff, J. Reimann, and H. Hauser. 2007. Tumor suppression by IFN regulatory factor-1 is mediated by transcriptional down-regulation of cyclin D1. Cancer Res. 67:2972–2981.
   PubMedGoogle Scholar
• Lee, J. C., J. T. Laydon, P. C. McDonnell, T. F. Gallagher, S. Kumar, D. Green, D. McNulty, M. J. Blumenthal, J. R. Heys, S. W. Landvatter, et al. 1994. A protein kinase involved in the regulation of inflammatory cytokine biosynthesis. Nature 372:739–746.
   PubMed Web of Science ®Google Scholar
• Liu, J., S. Cao, L. M. Herman, and X. Ma. 2003. Differential regulation of interleukin (IL)-12 p35 and p40 gene expression and interferon (IFN)-gamma-primed IL-12 production by IFN regulatory factor 1. J. Exp. Med. 198:1265–1276.
   PubMed Web of Science ®Google Scholar
• Loskog, A., H. Dzojic, S. Vikman, C. Ninalga, M. Essand, O. Korsgren, and T. H. Totterman. 2004. Adenovirus CD40 ligand gene therapy counteracts immune escape mechanisms in the tumor microenvironment. J. Immunol. 172:7200–7205.
   PubMed Web of Science ®Google Scholar
• Lou, Y., T. Z. Vitalis, G. Basha, B. Cai, S. S. Chen, K. B. Choi, A. P. Jeffries, W. M. Elliott, D. Atkins, B. Seliger, and W. A. Jefferies. 2005. Restoration of the expression of transporters associated with antigen processing in lung carcinoma increases tumor-specific immune responses and survival. Cancer Res. 65:7926–7933.
   PubMed Web of Science ®Google Scholar
• Mackey, M. F., J. R. Gunn, C. Maliszewski, H. Kikutani, R. J. Noelle, and R. J. Barth. 1998. Dendritic cells require maturation via CD40 to generate protective anti-tumour immunity. J. Immunol. 161:2094–2098.
   PubMed Web of Science ®Google Scholar
• Min, W., J. S. Pober, and D. R. Johnson. 1996. Kinetically coordinated induction of TAP1 and HLA class I by IFN-gamma: the rapid induction of TAP1 by IFN-gamma is mediated by Stat1 alpha. J. Immunol. 156:3174–3183.
   PubMed Web of Science ®Google Scholar
• Negishi, H., Y. Fujita, H. Yanai, S. Sakaguchi, X. Ouyang, M. Shinohara, H. Takayanagi, Y. Ohba, T. Taniguchi, and K. Honda. 2006. Evidence for licensing of IFN-gamma-induced IFN regulatory factor 1 transcription factor by MyD88 in Toll-like receptor-dependent gene induction program. Proc. Natl. Acad. Sci. USA 103:15136–15141.
   PubMed Web of Science ®Google Scholar
• Ninomiya-Tsuji, J., K. Kishimoto, A. Hiyama, J. Inoue, Z. Cao, and K. Matsumoto. 1999. The kinase TAK1 can activate the NIK-IκB as well as the MAP kinase cascade in the IL-1 signalling pathway. Nature 398:252–256.
   PubMed Web of Science ®Google Scholar
• Nozawa, H., E. Oda, K. Nakao, M. Ishihara, S. Ueda, T. Yokochi, K. Ogasawara, Y. Nakatsuru, S. Shimizu, Y. Ohira, K. Hioki, S. Aizawa, T. Ishikawa, M. Katsuki, T. Muto, T. Taniguchi, and N. Tanaka. 1999. Loss of transcription factor IRF-1 affects tumor susceptibility in mice carrying the Ha-ras transgene or nullizygosity for p53. Genes Dev. 13:1240–1245.
   PubMed Web of Science ®Google Scholar
• Perkins, N. D. 1997. Achieving transcriptional specificity with NF-κB. Int. J. Biochem. Cell Biol. 29:1433–1448.
   PubMed Web of Science ®Google Scholar
• Perkins, N. D. 2004. NF-κB: tumor promoter or suppressor? Trends Cell Biol. 14:64–69.
   PubMed Web of Science ®Google Scholar
• Pizzoferrato, E., Y. Liu, A. Gambotto, M. J. Armstrong, M. T. Stang, W. E. Gooding, S. M. Alber, S. H. Shand, S. C. Watkins, W. J. Storkus, and J. H. Yim. 2004. Ectopic expression of interferon regulatory factor-1 promotes human breast cancer cell death and results in reduced expression of survivin. Cancer Res. 64:8381–8388.
   PubMedGoogle Scholar
• Pullen, S. S., T. T. Dang, J. J. Crute, and M. R. Kehry. 1999. CD40 signaling through tumor necrosis factor receptor-associated factors (TRAFs). Binding site specificity and activation of downstream pathways by distinct TRAFs. J. Biol. Chem. 274:14246–14254.
   PubMedGoogle Scholar
• Pullen, S. S., M. E. Labadia, R. H. Ingraham, S. M. McWhirter, D. S. Everdeen, T. Alber, J. J. Crute, and M. R. Kehry. 1999. High-affinity interactions of tumor necrosis factor receptor-associated factors (TRAFs) and CD40 require TRAF trimerization and CD40 multimerization. Biochemistry 38:10168–10177.
   PubMedGoogle Scholar
• Rothe, M., V. Sarma, V. M. Dixit, and D. V. Goeddel. 1995. TRAF2-mediated activation of NF-κB by TNF receptor 2 and CD40. Science (Washington, DC) 269:1424–1427.
   PubMed Web of Science ®Google Scholar
• Rothman, P., B. Kreider, M. Azam, D. Levy, U. Wegenka, A. Eilers, T. Decker, F. Horn, H. Kashleva, J. Ihle, et al. 1994. Cytokines and growth factors signal through tyrosine phosphorylation of a family of related transcription factors. Immunity 1:457–468.
   PubMedGoogle Scholar
• Saccani, S., S. Pantano, and G. Natoli. 2002. p38-dependent marking of inflammatory genes for increased NF-κB recruitment. Nat. Immunol. 3:69–75.
   PubMed Web of Science ®Google Scholar
• Sakurai, H., S. Suzuki, N. Kawasaki, H. Nakano, T. Okazaki, A. Chino, T. Doi, and I. Saiki. 2003. Tumor necrosis factor-alpha-induced IKK phosphorylation of NF-κB p65 on serine 536 is mediated through the TRAF2, TRAF5, and TAK1 signaling pathway. J. Biol. Chem. 278:36916–36923.
   PubMed Web of Science ®Google Scholar
• Seliger, B., M. J. Maeurer, and S. Ferrone. 1997. TAP off—tumors on. Immunol. Today 18:292–299.
   PubMedGoogle Scholar
• Setiadi, A. F., M. D. David, S. S. Chen, J. Hiscott, and W. A. Jefferies. 2005. Identification of mechanisms underlying transporter associated with antigen processing deficiency in metastatic murine carcinomas. Cancer Res. 65:7485–7492.
   PubMedGoogle Scholar
• Stamenkovic, I., E. A. Clark, and B. Seed. 1989. A B-lymphocyte activation molecule related to the nerve growth factor receptor and induced by cytokines in carcinomas. EMBO J. 8:1403–1410.
   PubMed Web of Science ®Google Scholar
• Sun, Y., D. Peng, J. Lecanda, V. Schmitz, M. Barajas, C. Qian, and J. Prieto. 2000. In vivo gene transfer of CD40 ligand into colon cancer cells induces local production of cytokines and chemokines, tumor eradication and protective antitumor immunity. Gene Ther. 7:1467–1476.
   PubMed Web of Science ®Google Scholar
• Takahashi, S., R. F. Rousseau, P. Yotnda, Z. Mei, G. Dotti, D. Rill, R. Hurwitz, F. Marini, M. Andreeff, and M. K. Brenner. 2001. Autologous antileukemic immune response induced by chronic lymphocytic leukemia B cells expressing the CD40 ligand and interleukin 2 transgenes. Hum. Gene Ther. 12:659–670.
   PubMed Web of Science ®Google Scholar
• Tamura, T., H. Yanai, D. Savitsky, and T. Taniguchi. 2008. The IRF family transcription factors in immunity and oncogenesis. Annu. Rev. Immunol. 26:535–584.
   PubMed Web of Science ®Google Scholar
• Tanaka, N., T. Kawakami, and T. Taniguchi. 1993. Recognition DNA sequences of interferon regulatory factor 1 (IRF-1) and IRF-2, regulators of cell growth and the interferon system. Mol. Cell. Biol. 13:4531–4538.
   PubMed Web of Science ®Google Scholar
• Tong, A. W., and M. J. Stone. 2003. Prospects for CD40-directed experimental therapy of human cancer. Cancer Gene Ther. 10:1–13.
   PubMed Web of Science ®Google Scholar
• van Kooten, C., and J. Banchereau. 2000. CD40-CD40 ligand. J. Leukoc. Biol. 67:2–17.
   PubMed Web of Science ®Google Scholar
• Vonderheide, R. H., J. P. Dutcher, J. E. Anderson, S. G. Eckhardt, K. F. Stephans, B. Razvillas, S. Garl, M. D. Butine, V. P. Perry, R. J. Armitage, R. Ghalie, D. A. Caron, and J. G. Gribben. 2001. Phase I study of recombinant human CD40 ligand in cancer patients. J. Clin. Oncol. 19:3280–3287.
   PubMed Web of Science ®Google Scholar
• Vonderheide, R. H., K. T. Flaherty, M. Khalil, M. S. Stumacher, D. L. Bajor, N. A. Hutnick, P. Sullivan, J. J. Mahany, M. Gallagher, A. Kramer, S. J. Green, P. J. O'Dwyer, K. L. Running, R. D. Huhn, and S. J. Antonia. 2007. Clinical activity and immune modulation in cancer patients treated with CP-870,893, a novel CD40 agonist monoclonal antibody. J. Clin. Oncol. 25:876–883.
   PubMed Web of Science ®Google Scholar
• Wagner, A. H., M. Gebauer, B. Pollok-Kopp, and M. Hecker. 2002. Cytokine-inducible CD40 expression in human endothelial cells is mediated by interferon regulatory factor-1. Blood 99:520–525.
   PubMed Web of Science ®Google Scholar
• Wan, J., L. Sun, J. W. Mendoza, Y. L. Chui, D. P. Huang, Z. J. Chen, N. Suzuki, S. Suzuki, W. C. Yeh, S. Akira, K. Matsumoto, Z. G. Liu, and Z. Wu. 2004. Elucidation of the c-Jun N-terminal kinase pathway mediated by Estein-Barr virus-encoded latent membrane protein 1. Mol. Cell. Biol. 24:192–199.
   PubMedGoogle Scholar
• Wang, C.-Y., M. W. Mayo, and A. S. Baldwin, Jr. 1996. TNF- and cancer therapy-induced apoptosis: potentiation by inhibition of NF-kB. Science 274:784–787.
   PubMed Web of Science ®Google Scholar
• White, L. C., K. L. Wright, N. J. Felix, H. Ruffner, L. F. Reis, R. Pine, and J. P. Ting. 1996. Regulation of LMP2 and TAP1 genes by IRF-1 explains the paucity of CD8+ T cells in IRF-1−/− mice. Immunity 5:365–376.
   PubMedGoogle Scholar
• Williams, A., C. A. Peh, and T. Elliott. 2002. The cell biology of MHC class I antigen presentation. Tissue Antigens 59:3–17.
   PubMedGoogle Scholar
• Wright, K. L., L. C. White, A. Kelly, S. Beck, J. Trowsdale, and J. P. Ting. 1995. Coordinate regulation of the human TAP1 and LMP2 genes from a shared bidirectional promoter. J. Exp. Med. 181:1459–1471.
   PubMed Web of Science ®Google Scholar
• Yang, F., E. Tang, K. Guan, and C. Y. Wang. 2003. IKK beta plays an essential role in the phosphorylation of RelA/p65 on serine 536 induced by lipopolysaccharide. J. Immunol. 170:5630–5635.
   PubMed Web of Science ®Google Scholar
• Yarilina, A., K. H. Park-Min, T. Antoniv, X. Hu, and L. B. Ivashkiv. 2008. TNF activates an IRF1-dependent autocrine loop leading to sustained expression of chemokines and STAT1-dependent type I interferon-response genes. Nat. Immunol. 9:378–387.
   PubMed Web of Science ®Google Scholar
• Zhao, Z., Y. Qian, D. Wald, Y. F. Xia, J. G. Geng, and X. Li. 2003. IFN regulatory factor-1 is required for the up-regulation of the CD40-NF-κB activator 1 axis during airway inflammation. J. Immunol. 170:5674–5680.
   PubMedGoogle Scholar